Literature DB >> 33145264

Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then.

Takumi Kawaguchi1, Shigeo Shimose1, Sakura Yamamura1, Dan Nakano1, Masatoshi Tanaka2, Takuji Torimura1.   

Abstract

Entities:  

Year:  2020        PMID: 33145264      PMCID: PMC7575980          DOI: 10.21037/atm-2020-112

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
Prognostic factor is crucial for the management of hepatocellular carcinoma (HCC) patients. Based on large international databases, the albumin-bilirubin (ALBI) grade has originally been developed and is independently associated with overall survival in HCC patients (1). The usefulness of ALBI grade in predicting overall survival has been validated in patients with HCC underwent liver resection (2), radiofrequency ablation (3), and tyrosine kinase inhibitors (4,5). The prognostic impact of ALBI grade has also been reported in patients with intermediate-stage HCC underwent transarterial chemoembolization (TACE) (6). In addition, Zhao et al. recently demonstrated that ALBI grade was better than Child-Pugh class in terms of stratifying prognosis in patients with HCC underwent TACE (7). We summarize the recent progress in prediction of overall survival for patients with HCC underwent TACE by focusing on ALBI grade. We also discuss the future perspective of systematic predictive factors for patients with HCC underwent TACE. Liver function is associated with overall survival of patients with HCC (8). To assess liver function, Child-Pugh class has commonly been used and is better predictor of overall survival than model for end-stage liver disease score in patients with HCC underwent TACE (8). However, Child-Pugh class seems to have several limitations as followings. First, Child-Pugh class includes subjective parameters such as ascites and hepatic encephalopathy. Second, ascites and hepatic encephalopathy can be modified by medications. Third, prothrombin activity, a constitutive parameter of Child-Pugh class, can be affected by anticoagulant therapy. Fourth, each variable is assigned the same weight for the assessment of liver function. It is also important to re-recognize that Child-Pugh class is not applicable for patients with chronic hepatitis, because Child-Pugh class is designed for patients with liver cirrhosis. Recent progress in treatment for chronic hepatitis C and B virus infections causes an increase in the prevalence of non-cirrhotic patients with HCC. Moreover, the proportion of patients with non-alcoholic fatty liver disease-related HCC has been increasing and their liver function is often preserved (9). Thus, the shortcomings of Child-Pugh class and recent changes in characteristics of patients with HCC lead a question regarding an accuracy of Child-Pugh class as a prognostic factor for patients with HCC. In order to assess liver function for patients with HCC, Johnson et al. developed ALBI score, which is based on objective parameters such as serum levels of albumin and total bilirubin (1). The formula is {log10[total bilirubin level (mg/dL) × 17.1] × 0.66} + [serum albumin level (g/dL) × 10 × −0.085] and the ALBI score is classified into three grades as followings: grade 1 (≤−2.6), grade 2 (>−2.6 to ≤−1.39), and grade 3 (>−1.39) (1). Johnson et al. also reported that Child-Pugh class A can be divided into ALBI grade 1 and 2 (1), and there is a 10-month difference in overall survival between the ALBI grade 1 and 2 (1). Thus, ALBI grade is thought to accurately predict liver function as well as overall survival in patients with HCC. In fact, the majority of patients with HCC underwent TACE are classified as Child-Pugh class A (10). Peng et al. performed a systematic review to compare the prognostic ability of ALBI score versus Child-Pugh class in patients with HCC (11). They found that ALBI grade showed better than Child-Pugh class for predicting the prognosis in patients with HCC (11). However, it remains unclear if ALBI grade has higher predictive ability than Child-Pugh class in predicting overall survival of patients with HCC underwent TACE. Recently, Zhao et al. has compared the performance of ALBI grade and Child-Pugh class for predicting overall survival in HCC patients who underwent TACE (7). As a result, they enrolled 221 cirrhotic patients with Child-Pugh class A and HCC underwent TACE. In this study, time-dependent receiver operating characteristic curves have been employed to assess the predictive power of diagnostic markers for time-dependent disease outcomes (7). They clearly showed that the discriminatory ability of ALBI grade was better than Child-Pugh class for overall survival (7). The recent study by Zhao et al. demonstrated the superiority of ALBI grade than Child-Pugh class for predicting overall survival of patients with HCC underwent TACE (7). However, this study also has several limitations. First, this was a retrospective single center study, suggesting a selection bias. Secondary, the most of subjects were patients with hepatitis B viral-related HCC. It remains unclear if the superiority of ALBI grade is seen in patients with the non-viral hepatitis-related HCC including nonalcoholic fatty liver disease-related HCC, which is becoming a major etiology of HCC (9,12,13). Moreover, in this study, ALBI score >−2.6 to ≤−1.39 was classified to the ALBI grade 2, which covers a wide range of liver impairment. While, Hiraoka et al. proposed the modified ALBI (mALBI) grade, which divides ALBI grade 2 into two subgrades (grade 2a; >−2.6 to ≤−2.27 and grade 2b; >−2.27 to ≤−1.39) (5). Hiraoka et al. conducted a multi-center analysis, in which 6,649 naïve HCC patients were enrolled and demonstrated that mALBI grade has a better assessment ability for predicting overall survival than ALBI grade and Child-Pugh class (14). In addition, serum levels of albumin and bilirubin are affected by various factors other than liver function. Therefore, more precise model to evaluate liver function are still unmet needs. The platelet-albumin-bilirubin (PALBI) grade has recently been developed to reflect the effect of portal hypertension based on the ALBI grade (15). Although ALBI grade differentiates Child-Pugh class A patients into two groups, PALBI grade differentiates Child-Pugh class A patients into three groups (16). Jaruvongvanich et al. investigate the prognostic impact of 6 non-invasive models including, Child-Pugh class, ALBI, and PALBI in patients with HCC. They found that the PALBI is the most accurate prognostic model among 6 models to predict HCC recurrence and mortality (17). In addition, Lee et al. evaluated the ability of PALBI and ALBI grades to predict overall survival according to treatment modality in patients with HCC (18). They found that the ALBI grade showed high predictive ability for overall survival than PALBI in patients underwent surgical resection or radiofrequency ablation (18). While, the PALBI grade showed high predictive ability for overall survival than ALBI in patients underwent TACE or supportive care (18). Thus, proper use of the mALBI and PALBI grades based on the treatment modality may enable accurate determination of the prognosis of patients with HCC. Recent advances in prevention, diagnosis, and treatment for HCC lead a long-term survival of patients with HCC (19). As a result, the prevalence of aged patients with HCC has been increasing (20). Aging is known to alter immunity, and Li et al. performed a meta-analysis with 5,280 HCC patients from 22 studies and investigated an impact of neutrophil-to-lymphocyte ratio (NLR), which is an index of systemic inflammation and immune suppression on prognosis of patients with HCC (21). They demonstrated that NLR was identified as an independent factor associated with the presence of tumor vascular invasion and poor prognosis in patients with HCC underwent TACE (21). In addition, the prevalence of malnutrition increases according to aging. The controlling nutritional status (CONUT) score is a simple objective assessment tool of nutritional status (22). The CONUT score is based on following three variables: serum albumin level, total cholesterol level, and total lymphocyte count (22). The CONUT score has recently been reported as an independent prognostic factor for patients with HCC treated with lenvatinib in a multicenter cohort study (22). Moreover, the prevalence of sarcopenia is high in the elderly and sarcopenia is now recognized as an important prognostic factor independent from liver function in patients with HCC (23). Skeletal muscles play crucial roles in glucose, protein, and ammonia metabolisms (23). Moreover, skeletal muscle is known to release cytokines called myokines, which suppress proliferation of cancer cells (20,23). In fact, sarcopenia is a negative prognostic factor in patients with HCC underwent TACE (24). Loss of skeletal muscle mass during TACE is associated with poor prognosis in patients with HCC (25). While, in-hospital exercise maintains skeletal muscle mass during TACE (26,27) and has been reported to improve prognosis in patients with HCC underwent TACE (23). Thus, prognostic factors have been changing with the transition of the time. In conclusion, ALBI grade is more suitable for assessment of liver function than Child-Pugh class in patients with HCC underwent TACE. Because the most of such patients show mild liver dysfunction classified as Child-Pugh class A at present (). In addition, to improve the predictive accuracy, modification of ALBI such as mALBI and PALBI is better to be employed. Moreover, to adapt to the high prevalence of aging in patients with HCC, there is no doubt that assessment for general condition including immunity, nutrition, and skeletal muscle mass will become more important. Thus, NLR, CONUT, and sarcopenia should be considered as prognostic factors in near future ().
Figure 1

Changing in characteristics of patients with HCC underwent TACE and prognostic factor across the ages. HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; ALBI, albumin-bilirubin grade; mALBI, modified ALBI; PALBI, platelet-albumin-bilirubin grade; NLR, neutrophil-to-lymphocyte ratio; CONUT, controlling nutritional status.

Changing in characteristics of patients with HCC underwent TACE and prognostic factor across the ages. HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; ALBI, albumin-bilirubin grade; mALBI, modified ALBI; PALBI, platelet-albumin-bilirubin grade; NLR, neutrophil-to-lymphocyte ratio; CONUT, controlling nutritional status. The article’s supplementary files as
  27 in total

1.  Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Masashi Fujita; Atsushi Takahashi; Manabu Hayashi; Ken Okai; Kazumichi Abe; Hiromasa Ohira
Journal:  Hepatol Res       Date:  2019-04-25       Impact factor: 4.288

2.  A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hirofumi Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Koji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Hepatol Res       Date:  2017-08-02       Impact factor: 4.288

3.  Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.

Authors:  Daniel B Brown; Christopher E Fundakowski; Mauricio Lisker-Melman; Jeffrey S Crippin; Thomas K Pilgram; William Chapman; Michael D Darcy
Journal:  J Vasc Interv Radiol       Date:  2004-11       Impact factor: 3.464

4.  Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease.

Authors:  Shunji Koya; Takumi Kawaguchi; Ryuki Hashida; Emiko Goto; Hiroo Matsuse; Hiromichi Saito; Keisuke Hirota; Ryoko Taira; Yoshiko Matsushita; Minami Imanaga; Ayu Nagamatsu; Tomotake Shirono; Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Ryoko Kuromatsu; Hiroko Miura; Naoto Shiba; Takuji Torimura
Journal:  Hepatol Res       Date:  2016-05-05       Impact factor: 4.288

Review 5.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

6.  Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study.

Authors:  Soon Kyu Lee; Myeong Jun Song; Seok Hwan Kim; Misun Park
Journal:  PLoS One       Date:  2019-05-02       Impact factor: 3.240

7.  Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies.

Authors:  Sven H Loosen; Maximilian Schulze-Hagen; Philipp Bruners; Frank Tacke; Christian Trautwein; Christiane Kuhl; Tom Luedde; Christoph Roderburg
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

8.  Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization.

Authors:  Ezio Lanza; Riccardo Muglia; Isabella Bolengo; Dario Poretti; Felice D'Antuono; Roberto Ceriani; Guido Torzilli; Vittorio Pedicini
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

9.  Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma.

Authors:  Ryuki Hashida; Takumi Kawaguchi; Shunji Koya; Keisuke Hirota; Norihiro Goshima; Teruhito Yoshiyama; Takashi Otsuka; Masafumi Bekki; Sohei Iwanaga; Dan Nakano; Takashi Niizeki; Hiroo Matsuse; Atsushi Kawaguchi; Naoto Shiba; Takuji Torimura
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

10.  Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Takumi Kawaguchi; Sachiyo Yoshio; Yuzuru Sakamoto; Ryuki Hashida; Shunji Koya; Keisuke Hirota; Dan Nakano; Sakura Yamamura; Takashi Niizeki; Hiroo Matsuse; Takuji Torimura
Journal:  J Clin Med       Date:  2020-03-28       Impact factor: 4.241

View more
  1 in total

1.  Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis.

Authors:  Hiroki Kanno; Yuichi Goto; Shin Sasaki; Shogo Fukutomi; Toru Hisaka; Fumihiko Fujita; Yoshito Akagi; Koji Okuda
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.